ITM Isotope Technologies Munich (ITM) has signed an agreement with TerThera BV for supplies of Terbium-161 (Tb-161) to support the development of its Tb-161-based pipeline candidates.
Currently, ITM is investigating the use of Tb-161-based radiopharmaceuticals for treating various types of cancers. Like Lutetium-177, Tb-161 emits medium-range beta particles and has a similar half-life. However, Tb-161 also emits low-energy Auger and internal conversion electrons, delivering highly localized radiation that can effectively target isolated cancer cells and micro-metastases with minimal off-target effects, ITM noted.
